FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an Era?

Cancer

Volumn 117, Issue 15, 2011, Pages 3293-3304

  Pemmaraju, Naveen ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myeloid leukemia; cytogenetics; FLT3 protein; molecular abnormalities

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD135 ANTIGEN; CORE BINDING FACTOR BETA; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; ITR 260; KW 2449; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC EB10; MYOSIN HEAVY CHAIN; NUCLEOPHOSMIN; PLACEBO; PONATINIB; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; RETINOIC ACID RECEPTOR ALPHA; SB 1518; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CELL DAMAGE; CHROMOSOME 11Q; CHROMOSOME DELETION; CHROMOSOME DELETION 5; CHROMOSOME DELETION 7; CHROMOSOME TRANSLOCATION 11; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DYSGEUSIA; EDEMA; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; MONOSOMY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TANDEM REPEAT; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 79960696513     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25908     Document Type: Review

References (107)

1. Kelly LM, Gilliland DG., Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002; 3: 179-198. (Pubitemid 35217435)
2. American Cancer Society Web site. http:\\www.cancer.org Accessed August 8, 2010.
3. Horner MJ, Ries LAG, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2006 [based on the November 2008 SEER data submission, posted to the SEER website 2009.]. Bethesda, MD: National Cancer Institute; 2009. Access date.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Vol 1. Jenkentown, PA: NCCN; 2010.
5. Schiffer CA., Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med. 2003; 349: 727-729. (Pubitemid 37010775)
6. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474.
7. Ravandi F, Burnett AK, Agura ED, Kantarjian HM., Progress in the treatment of acute myeloid leukemia. Cancer. 2007; 110: 1900-1910. (Pubitemid 350041630)
8. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116: 354-365.
9. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333. (Pubitemid 28452973)
10. Downing JR., The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev. 2003; 13: 48-54. (Pubitemid 36143927)
11. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336. (Pubitemid 35429670)
12. Krauter J, Wagner K, Schafer I, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2009; 27: 3000-3006.
13. Schaich M, Schlenk RF, Al-Ali HK, et al. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica. 2007; 92: 763-770. (Pubitemid 350155301)
14. Kebriaei P, de Lima M, Estey E., Management of acute leukemias. In:, DeVita V, Lawrence T, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Vol 2. 8th ed. Philadelphia, PA: Lippencott Williams & Williams; 2008: 2232-2265.
15. Estey EH, Pierce S, Keating MJ., Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000; 85: 246-249. (Pubitemid 30340139)
16. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD., Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification ? Blood. 2007; 109: 431-448. (Pubitemid 46105936)
17. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W., Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics [serial online]. J Hematol Oncol. 2009; 2: 23.
18. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006; 107: 4011-4020. (Pubitemid 43726809)
19. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106: 3740-3746. (Pubitemid 41739007)
20. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106: 3733-3739. (Pubitemid 41739006)
21. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99: 4326-4335. (Pubitemid 34627197)
22. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: Cancer and Leukemia Group B study. Cancer Res. 2001; 61: 7233-7239. (Pubitemid 32946520)
23. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100: 4372-4380. (Pubitemid 35434129)
24. Kainz B, Heintel D, Marculescu R, et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J. 2002; 3: 283-289. (Pubitemid 36167783)
25. Ciolli S, Vannucchi AM, Leoni F, et al. Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia. Leuk Lymphoma. 2004; 45: 73-78. (Pubitemid 38181396)
26. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006; 107: 3724-3726.
27. Kiyoi H, Naoe T,. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol. 2006; 83: 301-308. (Pubitemid 43807573)
28. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008; 111: 1552-1559. (Pubitemid 351213445)
29. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE,. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007; 110: 1262-1270. (Pubitemid 47281424)
30. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004; 103: 1901-1908. (Pubitemid 38268989)
31. Kang HJ, Lee JW, Kho SH, et al. High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. J Korean Med Sci. 2010; 25: 841-845.
32. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G,. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006; 24: 790-797. (Pubitemid 46622046)
33. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood. 2003; 102: 1613-1618. (Pubitemid 37022550)
34. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006; 108: 3898-3905. (Pubitemid 44864574)
35. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002; 20: 3254-3261. (Pubitemid 34831523)
36. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000; 14: 796-804. (Pubitemid 30235055)
37. Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S,. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica. 2005; 90: 881-889. (Pubitemid 41024890)
38. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005; 106: 3618-3620. (Pubitemid 41609201)
39. Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005; 11: 1416-1424. (Pubitemid 40315221)
40. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003; 4: 31-40. (Pubitemid 36927158)
41. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22: 624-633. (Pubitemid 41095065)
42. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002; 100: 2717-2723.
43. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005; 23: 9234-9242.
44. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28: 2348-2355.
45. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2010; 28: 3717-3723.
46. Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116: 788-792.
47. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008; 26: 4595-4602.
48. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009; 115: 3719-3727.
49. Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21: 550-551, 2007; author reply 552.
50. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008; 26: 5429-5435.
51. Bacher U, Kohlmann A, Haferlach C, Haferlach T., Gene expression profiling in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol. 2009; 22: 169-180.
52. Larson RA., Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. Chem Biol Interact. 2010; 184: 21-25.
53. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918. (Pubitemid 351620111)
54. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352: 254-266. (Pubitemid 40110814)
55. Litzow MR., More flitting about FLT3. Blood. 2005; 106: 3331-3332. (Pubitemid 41609152)
56. Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells. Blood. 1993; 82: 1110-1119. (Pubitemid 23253983)
57. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D., Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 1991; 6: 1641-1650. (Pubitemid 21924268)
58. Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005; 121: 295-306. (Pubitemid 40546396)
59. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR., Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995; 3: 147-161.
60. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 2008; 180: 7358-7367.
61. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100: 59-66. (Pubitemid 35177429)
62. Grundler R, Miething C, Thiede C, Peschel C, Duyster J., FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005; 105: 4792-4799. (Pubitemid 40807305)
63. Breitenbuecher F, Schnittger S, Grundler R, et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009; 113: 4074-4077.
64. Frohling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002; 20: 2480-2485. (Pubitemid 34525733)
65. Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006; 107: 3700-3707.
66. Kottaridis PD, Gale RE, Frew ME, et al. The presence of an FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98: 1752-1759.
67. Schnittger S, Weiss T, Haferlach C, Kern W, Haferlach T., Prognostic impact of FLT3 mutation load in NPM1 mutated AML [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 826.
68. Breccia M, Frustaci AM, Cannella L, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009; 27: 148-153.
69. Emerenciano M, Menezes J, Vasquez ML, et al. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. Leuk Lymphoma. 2008; 49: 2291-2297.
70. Shimada A, Taki T, Tabuchi K, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Pediatr Blood Cancer. 2008; 50: 264-269.
71. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006; 108: 3654-3661. (Pubitemid 44864541)
72. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002; 1: 433-443. (Pubitemid 41039124)
73. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008; 111: 5663-5671.
74. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008; 22: 808-818. (Pubitemid 351552630)
75. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101: 3597-3605. (Pubitemid 36857948)
76. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009; 114: 1607-1617.
77. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009; 114: 2984-2992.
78. Rivera VM, Xu Q, Berk L, et al. Potent antitumor activity of AP24534, an orally active inhibitor of bcr-abl, Flt3 and other kinases, in both in vitro and in vivo models of acute myeloid leukemia (AML) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 2932.
79. Hart S, Goh KC, Tan YC, Amalini C, Wood JM., SB1518, a novel oral JAK2-FLT3 inhibitor, is efficacious in models of acute myeloid leukemia and primary leukemic cells from patients [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Res. (AARC); Washington, DC; April 17-21, 2010. Philadelphia, PA: AARC; 2010. Abstract 2524.
80. Liu C-P, Liu HE, Lee O, et al. ITRI-260, a promising candidate for treatment of acute myeloid leukemia [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Res. (AARC); Washington, DC; April 17-21, 2010. Philadelphia, PA: AARC; 2010. Abstract LB-160.
81. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M., FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010; 115: 1425-1432.
82. Youssoufian H, Rowinsky EK, Tonra J, Li Y., Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. Cancer. 2010; 116: 1013-1017.
83. Pemmaraju N, Kantarjian HM, Ravandi F, et al. FLT3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 1026.
84. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103: 3669-3676. (Pubitemid 38596280)
85. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006; 108: 3262-3270.
86. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006; 108: 3477-3483.
87. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001; 19: 1485-1492. (Pubitemid 32202557)
88. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005; 105: 54-60. (Pubitemid 40053063)
89. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010; 28: 4339-4345.
90. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008; 100: 184-198. (Pubitemid 351480557)
91. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
92. Quintas-Cardama A, Kantarjian H, Andreef M, et al. Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML) [abstract]. J Clin Oncol. 2007; 25 (18S; June 20 suppl): Abstract 7018.
93. Pratz KW, Cho E, Karp J, et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 7065.
94. Crump M, Hedley D, Kamel-Reid S, et al. A randomized phase I clinical and biologic study of 2 schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: an NCIC (National Cancer Institute of Canada) Clinical Trials Group study. Leuk Lymphoma. 2010; 51: 252-260.
95. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009; 113: 6567-6571.
96. Safaian NN, Czibere A, Bruns I, et al. Sorafenib (nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2009; 33: 348-350.
97. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-7109. (Pubitemid 39331023)
98. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005; 105: 986-993. (Pubitemid 40170865)
99. Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 636.
100. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009; 113: 3938-3946.
101. Kyowa Pharmaceutical, Inc. Safety, Tolerability, and Pharmacokinetic/ Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia. National Clinical Trials identifier NTC00779480. Accessed April 26, 2010.
102. Levis M, Pham R, Smith BD, Small D., In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004; 104: 1145-1150. (Pubitemid 39038036)
103. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 788.
104. Stone RM, Fischer T, Paquette R, et al. A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3 [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 634.
105. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28: 1856-1862.
106. Stirewalt DL, Radich JP., The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3: 650-665. (Pubitemid 37328820)
107. Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009; 114: 2386-2392.